Related references
Note: Only part of the references are listed.Combined Proteomic and Genetic Interaction Mapping Reveals New RAS Effector Pathways and Susceptibilities
Marcus R. Kelly et al.
CANCER DISCOVERY (2020)
Hyperactivation of MAPK Signaling Is Deleterious to RAS/RAF-mutant Melanoma
Grace P. Leung et al.
MOLECULAR CANCER RESEARCH (2019)
WRN helicase is a synthetic lethal target in microsatellite unstable cancers
Edmond M. Chan et al.
NATURE (2019)
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens
Fiona M. Behan et al.
NATURE (2019)
Exploring genetic interaction manifolds constructed from rich single-cell phenotypes
Thomas M. Norman et al.
SCIENCE (2019)
Architecture of autoinhibited and active BRAF-MEK1-14-3-3 complexes
Eunyoung Park et al.
NATURE (2019)
Paralog buffering contributes to the variable essentiality of genes in cancer cell lines
Barbara De Kegel et al.
PLOS GENETICS (2019)
Werner Syndrome Helicase Is Required for the Survival of Cancer Cells with Microsatellite Instability
Lorn Kategaya et al.
ISCIENCE (2019)
GEMINI: a variational Bayesian approach to identify genetic interactions from combinatorial CRISPR screens
Mahdi Zamanighomi et al.
GENOME BIOLOGY (2019)
Orthologous CRISPR-Cas9 enzymes for combinatorial genetic screens
Fadi J. Najm et al.
NATURE BIOTECHNOLOGY (2018)
A Convergence-Based Framework for Cancer Drug Resistance
David J. Konieczkowski et al.
CANCER CELL (2018)
Oncogenic Signaling Pathways in The Cancer Genome Atlas
Francisco Sanchez-Vega et al.
CELL (2018)
Mapping the Genetic Landscape of Human Cells
Max A. Horlbeck et al.
CELL (2018)
Combinatorial CRISPR-Cas9 Metabolic Screens Reveal Critical Redox Control Points Dependent on the KEAP1-NRF2 Regulatory Axis
Dongxin Zhao et al.
MOLECULAR CELL (2018)
Genome-scale analysis identifies paralog lethality as a vulnerability of chromosome 1p loss in cancer
Srinivas R. Viswanathan et al.
NATURE GENETICS (2018)
Systematic analysis of complex genetic interactions
Elena Kuzmin et al.
SCIENCE (2018)
Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions
Kyuho Han et al.
NATURE BIOTECHNOLOGY (2017)
Combinatorial CRISPR-Cas9 screens for de novo mapping of genetic interactions
John Paul Shen et al.
NATURE METHODS (2017)
Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening
E. Robert McDonald et al.
CELL (2017)
Defining a Cancer Dependency Map
Aviad Tsherniak et al.
CELL (2017)
BAGEL: a computational framework for identifying essential genes from pooled library screens
Traver Hart et al.
BMC BIOINFORMATICS (2016)
Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9
John G. Doench et al.
NATURE BIOTECHNOLOGY (2016)
Treating cancer with selective CDK4/6 inhibitors
Ben O'Leary et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5
Konstantinos J. Mavrakis et al.
SCIENCE (2016)
MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells
Gregory V. Kryukov et al.
SCIENCE (2016)
A global genetic interaction network maps a wiring diagram of cellular function
Michael Costanzo et al.
SCIENCE (2016)
The regulation of oncogenic Ras/ERK signalling by dual-specificity mitogen activated protein kinase phosphatases (MKPs)
Andrew M. Kidger et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2016)
Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants
Lisa Brenan et al.
CELL REPORTS (2016)
ERK Mutations Confer Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors
Eva M. Goetz et al.
CANCER RESEARCH (2014)
ARID1B is a specific vulnerability in ARID1A-mutant cancers
Katherine C. Helming et al.
NATURE MEDICINE (2014)
Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations
X. Chen et al.
ONCOGENE (2014)
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
Meghna Das Thakur et al.
NATURE (2013)
EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF-Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib
Ryan B. Corcoran et al.
CANCER DISCOVERY (2012)
Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
Nikhil Wagle et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
Jessie Villanueva et al.
CANCER CELL (2010)
Post-translational regulation of mitogen-activated protein kinase phosphatase-2 (MKP-2) by ERK
Dong-Jun Peng et al.
CELL CYCLE (2010)
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Georgia Hatzivassiliou et al.
NATURE (2010)
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Cory M. Johannessen et al.
NATURE (2010)
Melanomas acquire resistance toB-RAF(V600E) inhibition by RTK or N-RAS upregulation
Ramin Nazarian et al.
NATURE (2010)
Structural basis of docking interactions between ERK2 and MAP kinase phosphatase 3
SJ Liu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Global mapping of the yeast genetic interaction network
AHY Tong et al.
SCIENCE (2004)
Dual specificity phosphatases: a gene family for control of MAP kinase function
M Camps et al.
FASEB JOURNAL (2000)
Share Paper
